By proceeding, you agree to our Terms of Use and Privacy Policy.
Dr. Eisner, Chief Medical Officer joined the Company in December 2020, overseeing all global clinical development and regulatory affairs for FibroGen. Dr.
Talks About #healthcare
Preferred Locations #NorthAmerica
With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.